We have identified a novel 7.7 Mb del(8)(q23.2q24.11) in a patient progressing to acute myeloid leukemia (AML) following a 12-year stable phase of chronic myelomonocytic leukemia (CMML). A surprisingly high JAK2 þ allelic burden of 92% at the time of AML led us to delineate the molecular aberrations relevant for leukemogenesis. While a frameshift mutation in the TET2 gene was stably present throughout the course of disease the JAK2 mutation was acquired after initial diagnosis of CMML. At progression aCGH revealed del(8q)(q23.2q24.11) encompassing various cancer relevant genes of which RAD21 and CSMD3 are of particular interest.
Introduction
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell neoplasm with overlapping myelodysplastic and myeloproliferative features. While progression to acute myeloid leukemia (AML) is common, the driving molecular aberrations involved in transformation remain obscure [1] . Clonal cytogenetic abnormalities predict adverse prognosis and are evident in up to 40% of cases [2] . Next generation sequencing has identified molecular aberrations in approximately 90% of CMML patients with TET2 gene mutations (TET2þ ) being particularly frequent. On the contrary, the JAK2 V617F mutation (JAK2 þ) is uncommon [3] . Concomitant TET2 þ and JAK2 þ have been described in chronic myeloproliferative disorders, but none of these are sufficient to drive blastic transformation. Moreover, transformation of myeloproliferative disorders most often results in loss of JAK2þ indicating the transformation to arise in a JAK2-negative subclone [4] . We here report a case of TET2þ CMML who acquired JAK2 þ and progressed into overt AML 12 years after initial diagnosis. Array comparative genomic hybridization (aCGH) revealed a novel del(8q)(q23.2q24.11) (del(8q)) comprising genes with recently reported relevance in cancer, including AML.
Case presentation
In 1998, a 64-year old male presented with pleural effusion, pericarditis, and leukocytosis of 38 Â 10 9 /L with 30% monocytes. A complete overview of the clinical course of disease is given in Table 1 . A bone marrow (BM) biopsy revealed CMML-1. There was no splenomegaly or cytopenias. In 2004, pleural effusion reemerged and microscopy of pleural fluid revealed numerous CD68 positive monocytes. Lymph node enlargement emerged in 2007 and a biopsy showed infiltration of 50% fully differentiated monocytes. Despite these various CMML-related manifestations, no cytopenias were evident. However, in 2010 BM failure developed with decreasing hemoglobin and thrombocyte counts and increasing leukocyte count. Morphology revealed persistent CMML-1. Nine months later, in June 2011 at the age of 76 the patient was admitted with abdominal pain and severely deranged hematopoiesis and was diagnosed with AML. Flow cytometry of peripheral blood showing 40% myeloblasts staining positive for CD34, CD117, HLA-DR, and CD13. A CT scan showed splenomegaly, and signs of malignant infiltration in the renal parenchyma and the soft tissue along the lower thoracic vertebras, suspicious of myelosarcomas. The patient received palliative care, but succumbed from progressive renal failure in July 2011. Routine molecular analysis at AML diagnosis showed a JAK2þ allelic burden of 92% of mononuclear cells (MNCs) from peripheral blood (PB). Since JAK2 þ is usually lost upon transformation this led us to retrospectively delineate the longitudinal evolution of molecular aberrations at critical time points, summarized in Table 1 .
In short, DNA was extracted from diagnostic paraffin embedded BM biopsies (1998), from thawed BM MNCs from the time of disease progression (2010), and from PB MNCs at the time of overt AML (2011). JAK2 þ was analyzed for by standard quantitative polymerase chain reaction (qPCR). While the diagnostic CMML sample was negative for JAK2 þ, the allelic burden was above the 90% level both in the transformation-and AML phase of disease. The entire coding sequences and all splice sites of the TET2 gene (exons 3-11) were scanned for mutations by PCR combined with denaturing gradient gel electrophoresis (DGGE) as described in Ref. [5] . In all samples, a stable frameshift mutation in exon 6 was found (c.3658_3658del A, Thr1220fs. RefSeq NM_001127208.2). DNA extracted from a benign skin biopsy from 1990 proved negative for TET2 mutations, hence excluding germline mutation (Fig. 1A) . By multiplex fluorescent-labeled PCR followed by capillary gel electrophoresis we retrospectively analyzed MNCs from the time of AML-diagnosis for recurrent AML related mutations, namely FLT3-ITD, FLT3-D835, cKIT D816V, IDH1 R132, CEBPA, NPM1 exon 12, and WT1 exon 7 of which all came out negative. Standard G-band karyotyping was not performed at initial diagnosis in 1998, but the karyotype was 46,XY[20] two and a half years from diagnosis in stable phase of disease. However, in September 2010 the karyotype had changed to 46,XY,dup(9)(p21p21) [6] /46,XY [19] .
Since progressive BM failure was not evident until September 2010, we considered this time point pivotal in AML transformation. Consequently, we focused on identifying candidate aberrations of potential impact by applying aCGH using human Cancer CytoChip at this time point. Regions of gain or loss contained within copy number variable regions (CNVs) were discarded. Reference genome was NCBI build 36.1 (hg18). High-resolution aCGH analysis revealed an interstitial deletion in chromosome 8 at bands q23.2-q24.11 of maximal size 7,7 Mb (position 110.679.916-118.334.826) (Fig. 1B and C (Fig. 1D) . Array CGH did not detect the dup(9) (p21p21) found with standard G-banding karyotyping in September 2010, since the fraction of dup (9) positive cells is below the sensitivity of aCGH.
The region 8q23.2-q24.11 encompasses genes as depicted in Fig. 1C . We performed an NCBI gene database and PubMed search on each of these genes for their reported relevance in carcinogenesis. Importantly, several of these are of notified relevance; TRPS1 and EIF3H are reported as candidate oncogenes with increased expression in breast cancer [6, 7] . In a study of non-small cell lung carcinomas the CUB and sushi multiple domains 3 gene (CSMD3) was identified as the second most frequently mutated gene and loss of function cause increased proliferation of airway epithelial cells in vitro [8] . While the CSMD gene family has recently been suggested tumor suppressor genes in colorectal cancer [9] , the role of CSMD3 in hematological cancers remains to be elucidated. Strikingly, RAD21 has been associated with AML as it encodes a protein in the cohesin complex, which is involved in chromosome segregation during cell division, regulation of transcription, and DNA double strand break repair. Recently, genes belonging to the cohesin complex were described as novel recurrent and mutually exclusive mutations in myeloid neoplasms [10] . 
Conclusion
We have longitudinally described the molecular aberrations present at critical time points from initial diagnosis of CMML to overt AML applying a comprehensive panel of molecular analyses. Firstly, the consistent and non-germ line TET2 þ in all stages of disease verify that the AML stage indeed was transformed from CMML and not a de novo event. Secondly, in this case, TET2 þ and JAK2 þ represent founder mutations. It cannot be ruled out that the massive JAK2 þ allelic burden have contributed to genomic instability and, speculatively, also influenced the proliferative potential of the leukemic blasts. Thirdly, aCGH revealed a novel del(8q). Our results indicate that the leukemic transformation of an otherwise long-standing and stable CMML could have been driven by loss of gene function resulting from this exact deletion. Of the deleted genes, RAD21 and CSMD3 are of particular interest, since their loss of function have recently been reported to play a role in carcinogenesis. However, their role in hematological cancers remains to be studied. Finally, this case report emphasizes the relevance of aCGH in the search for candidate genes involved in leukemogenesis, not least in heterogeneous neoplasms such as CMML.
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